Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease
In a retrospective observational study based on provider assessments and chart review: Providers reported cognitive improvement in 92% of patients following initiation of ZUNVEYL Providers reported improvement in neuropsychiatric symptoms in 93% of patients after initiation of ZUNVEYL Providers reported delayed initiation or discontinuation of concomitant psychotropic medications in 80% of patients receiving ZUNVEYL Providers […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.